Crinetics Share Price

Crinetics Share Price

NASDAQ: CRNX | Healthcare
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Crinetics Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
N/A
Volume
N/A
Average Traded
N/A

Crinetics Share Price Chart

$0.00$0.00
L
Show Current Price
H

Crinetics Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-4.73
Revenue (TTM)
$7.70B
Return On Equity (TTM)
-42.08%
Profit Margin
-6043.12%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
7.10%

Crinetics Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.14$6.16$10.73$25.12
Net Profit-$130.09-$122.82-$127.85-$120.86
Net Profit Margin-92921.43%-1993.83%-1191.52%-481.13%
Income ChangeN/A5.59%-4.10%5.47%

Crinetics Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$4.74$4.01$1.04$7.70
Net Profit-$163.92-$214.53-$298.41-$465.32
Net Profit Margin-3458.23%-5349.88%-28693.27%-6043.12%
Income ChangeN/A-30.87%-39.10%-55.93%

Crinetics Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets77.9259.261.26.99
Current Assets1048.341375.39574.15345.18
Total Assets1126.261434.59635.35352.18
Non Current Liabilities49.150.152.318.13
Current Liabilities85.0759.6843.9427.72
Total Liabilities134.17109.7996.2535.85
Shareholders' Equity992.081324.81539.11316.33

Crinetics Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-377.92-230.19-168.6-115.21
Investing173.91-574.82-200.41-173.98
Financing40.611,014.66391.24121.96

About Crinetics

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Crinetics Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %

Crinetics Share Price FAQs